Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients

Cardiovascular Research

Volumn 34, Issue 1, 1997, Pages 73-80

  Schotborgh, Carl E ^a   Wilde, Arthur A M ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Arrhythmias; ATP sensitive; Diabetes; Myocardial infarction; Myocardial ischemia; Potassium channel; Sulfonylureas

Indexed keywords

POTASSIUM CHANNEL; SULFONYLUREA DERIVATIVE;

BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CHANNEL GATING; DIABETES MELLITUS; ENERGY METABOLISM; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HYPOGLYCEMIA; MEMBRANE CURRENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ARRHYTHMIA; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; POTASSIUM CHANNELS; SULFONYLUREA COMPOUNDS;

EID: 0030909459     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00036-9     Document Type: Review

References (88)

1. Aquilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the β cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995;268:423-426.
2. KATP: an inward rectifier subunit plus the sulphonylurea receptor. Science 1995;270:1166-1170.
3. + channel in the mitochondrial inner membrane. Nature 1991;352:244-247.
4. + channel from rat liver and beef heart mitochondria. J Biol Chem 1992;267:26062-26069.
5. ATP channel as a receptor for potassium channel openers. J Biol Chem 1996;271:8796-8799.
6. + channels. Neuron 1996;16:1011-1017.
7. Chutkow WA, Simon C, Le Beau M, Burant CF. Cloning, tissue expression, and chromosomal localization of SUR2, the putative drug-binding subunit of cardiac, skeletal muscle, and vascular KATP channels. Diabetes 1996;45:1439-1445.
8. + channel. J Biol Chem 1996;271:24321-24324.
9. Quayle JM, Standen NB. K.ATP channels in vascular smooth muscle. Cardiovasc Res 1994;28:797-804.
10. Hearse DJ. Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Cardiovasc Res !995;30:1-17.
11. + channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571-581.
12. Mitani A, Kinoshita K, Fukamachi K, et al. Effects of glibenclamide and nicorandil on cardiac function during ischemia and reperfusion. Am J Physiol 1991;261:H1864-H1871.
13. + channel opener aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of hemodynamic changes. J Pharmacol Exp Ther 1991;259:961-967.
14. Auchampach JA, Maruyama M, Cavero I, Gross GJ. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation 1992;86:311-319.
15. Leibowitz G, Cerasi E. Sulphonylurea treatment in NIDDM patients with cardiovascular disease: a mixed blessing. Diabetologica 1996;39:503-514.
16. Wilde AAM, Janse MJ. Electrophysiological effects of ATP-sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res 1994;28:16-24.
17. Smits P, Thien T. Cardiovascular effects of sulphonylurea derivatives. Implications for the treatment of NIDDM. Diabetologica 1995;38:116-121.
18. + currents in pancreatic β-cells. Naunyn-Schmiedebergs Arch Pharmacol 1988;337:225-230.
19. Sartor G, Melander A, Scherstén B, Wåhlin-Boll E. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. Diabetologia 1980;18:17-22.
20. + loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle. Circ Res 1991;69:623-637.
21. ATPchannels by glibenclamide in rat ventricular myocytes. J Cardiovasc Electrophysiol 1993;438-447.
22. + channels in cardiac muscle by the sulphonylurea drug glibenclamide. J Pharmacol Exp Ther 1992;261:540-545.
23. + channel in insulin-secreting cells. J Biol Chem 1987;262:15840-15844.
24. Sturgess NC, Kozlowski RZ, Carrington CA, et al. Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line. Br J Pharmacol 1988;95:83-94.
25. + channels in cardiac muscle. J Pharmacol Exp Ther 1992;262:71-79.
26. + channels during metabolic stress in cardiac muscle. J Pharmacol Exp Ther 1993;266:456-467.
27. - conductance. Circ Res 1995;77:417-423.
28. + channel regulators on cystic fibrosis transmembrane conductance regulator chloride currents. J Gen Physiol 1992;100:573-591.
29. + channel in mouse pancreatic β-cells. Pflügers Arch 1986;407:493-499.
30. + current in the human neuroblastoma cell line SH-SY5Y. Neurosci Lett 1992;135:37-40.
31. + channel in rat vascular muscle. J Vase Res 1994;31:256-264.
32. + channels by cromakalim, pinacidil and glyburide. Biophys J 1990;57:509a(Abstract).
33. Xiong Z, Kajioka S, Sakai T, et al. Pinacidil inhibits the ryanodine-sensitive outward current and glibenclamide antagonizes its action in cells from the rabbit portal vein. Br J Pharmacol 1991;102:788-790.
34. Chopra LC, Twort CHC, Ward JPT. Direct action of BRL 38227 and glibenclamide on intracellular calcium stores in cultured airway smooth muscle of rabbit. Br J Pharmacol 1992;105:259-260.
35. + channels in the sarcoplasmatic reticulum membranes. Pflügers Arch 1987;409:374-380.
36. Kramer JH, Lampson WG, Schaffer SW. Effect of tolbutamide on myocardial energy metabolism. Am J Physiol 1983;245:H313-H319.
37. Tan BH, Wilson GL, Schaffer SW. Effect of tolbutamide on myocardial metabolism and mechanical performance of the diabetic rat. Diabetes 1984;33:1138-1143.
38. Cook GA. The hypoglycemic sulphonylureas glyburide and tolbutamide inhibit fatty acid oxidation by inhibiting carnitine palmitoyltransferase. J Biol Chem 1987;262:4968-4972.
39. + channels. Evidence for preferential regulation by glycolysis. J Gen Physiol 1989:94:911-935.
40. Wilde AAM, Escande D, Schumacher CA, et al. Potassium accumulation in the globally ischemic mammalian heart: A role for the ATP-sensitive potassium channel. Circ Res 1990;67:835-843.
41. + channels and lactate-coupled efflux. Eur J Pharmacol 1993;236:107-112.
42. Wilde AAM, Aksnes G. Myocardial potassium loss and cell depolarization in ischemia and hypoxia. Cardiovasc Res 1995;29:1-15.
43. Harvey RD, Hume JR. Autonomic regulation of a chloride current in heart. Science 1989;244:983-985.
44. Ruiz Petrich E, Zumino AP, Schanne OF. Early action potential shortening in hypoxic hearts: role of chloride current(s) mediated by catecholamine release. J Mol Cell Cardiol 1996;28:279-290.
45. Benndorf K, Friedrich M, Hirche Hj. Anoxia opens ATP regulated K channels in isolated heart cells of the guinea pig. Pflügers Arch 1991;419:108-110.
46. + currents in isolated ventricular myocytes. Cardiovasc Res 1996;32:930-939.
47. Veldkamp MW, van Ginneken ACG, Opthof T, Wilde AAM, Bouman LN. Metabolic inhibition induced action potential shortening coincides with an increase in whole-cell outward current, but not with the opening of single K.ATP channels in the patch membrane. Submitted 1996.
48. + loss, reduction in repolarization time, and tissue ATP levels during myocardial hypoxia and ischemia. Circ Res 1993;72:560-570.
49. Cascio WE, Yan G, Kleber AG. Early changes in extracellular potassium in ischemic rabbit myocardium. The role of extracellular carbon dioxide accumulation and diffusion. Circ Res 1992;70:409-422.
50. Schaffer S, Carr LJ, Prussel E, Ramasamy R. Effects of glycogen depletion on ischemic injury in isolated rat hearts: insights into preconditioning. Am J Physiol 1995;268:H935-H944.
51. Cross HR, Opie LH, Radda GK, Clarke K. Is a high glycogen content beneficial or detrimental to the ischemic rat heart? Circ Res 1996;78:482-491.
52. Wissner SB. The effect of excess lactate upon the excitability of the sheep Purkinje fiber. J Electrocardiol 1974;7:17-26.
53. Keung EC, Li Q. Lactate activates ATP-sensitive potassium channels in guinea pig ventricular myocytes. J Clin Invest 1991;88:1772-1777.
54. Wolfe CE, Sievers RE, Visseren FJL, Donelly TJ. Loss of myocardial protection after preconditioning correlates with the time course of glycogen recovery within the preconditioned segment. Circulation 1993;87:881-892.
55. + ATP channel blockade on interstitial adenosine accumulation in ischemic rabbit myocardium. Basic Res Cardiol 1995;90:410-417.
56. Sato T, Obata T, Yamanaka Y, Arita M. Glibenclamide decreases adenosine production in rat hearts by inhibiting 5′-nucleotidase. Circulation 1996;94(suppl I):I-364(Abstract).
57. Kitakaze M, Hori M, Morioka T, et al. Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5′-nucleotidase activity and attenuation of adenosine release. Circulation 1994;89:1237-1246.
58. Sanquinetti MC. Modulation of potassium channels by antiarrhythmic and antihypertensive drugs. Hypertension 1992;19:228-236.
59. Garcia MJ, McNamara PM, Gordon T, Kannell WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105-111.
60. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 1985;8:230-234.
61. Groop LC. Sulphonylureas in NIDDM. Diabetes Care 1992;15:737-754.
62. Anonymous. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results: University Group Diabetes Program. Diabetes 1970;19(suppl 2):747-830.
63. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972;21:976-979.
64. Feinstein AR. Clinical biostatistics. XXXV. The persistent clinical failures and fallacies of the UGPD study. Clin Pharmacol Ther 1976;19:78-93.
65. Kilo C, Miller JP, Williamson JR. The Achilles heel of the University Group Diabetes Program. J Am Med Assoc 1980;243:450-457.
66. Huupponen R. Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance. Med Toxicol 1987;2:190-209.
67. Yudkin JS, Oswald GA. Determinants of hospital admission and case fatality in diabetic patients with myocardial infarction. Diabetes Care 1988;11:351-358.
68. Ulvenstam G, Aberg A, Bergstrand R, et al. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes 1985;34:787-792.
69. Nahser PJ, Brown RE, Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 1995;91:635-640.
70. Kosmas EN, Levy RD, Hussain SNA. Acute effects of glyburide on the regulation of peripheral blood flow in normal humans. Eur J Pharmacol 1995;274:193-199.
71. Bijlstra PJ, Lutterman JA, Russell FGM, Thien T, Smits P. Interaction of sulphonylurea derivatives with vascular ATP sensitive channels in humans. Diabetologia 1996;39:1083-1090.
72. Groop L, Groop PH, Stenman S, et al. Comparison of pharmacokinetics, metabolic effects and action of glyburide and glipizide during long-term treatment. Diabetes Care 1987;10:671-678.
73. Crooks MJ, Brown KF. The binding of sulphonylureas to serum albumin. J Pharm Pharmacol 1974;26:304-311.
74. + channels: interactions between glyburide and potassium channel openers. J Vase Res 1993;30:2-12.
75. Chan JCN, Tomlinson B, Critchley JAJH, Cockram CS, Waiden RJ. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 1993;16:1035-1038.
76. + channel blocker. Circulation 1994;90:700-705.
77. + channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 1995;77:1030-1035.
78. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 1995;91:37-47.
79. Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits infarct size. A role for ischemic preconditioning. Circulation 1995;91:291-297.
80. Cacciapuoti F, Spiezia R, Bianchi U et al. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol 1991;67:843-847.
81. Lomuscio A, Vergani D, Marano L, Castagnone M, Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coron Artery Dis 1994;5:767-771.
82. Davis TME, Parsons RW, Broadhurst R, Hobbs M, Jamrozik K. Arrhythmias and mortality after myocardial infarction in diabetic patients: relationship to diabetes treatment. Diabetologia 1996;39(suppl 1):A51 (Abstract).
83. Soler NG, Pentecost BL, Bennett MA, et al. Coronary care for myocardial infarction in diabetics. Lancet 1974;l:475-477.
84. Lichstein E, Kuhn LA, Goldburg E, et al. Diabetic treatment and primary ventricular fibrillation in acute myocardial infarction. Am J Cardiol 1976;38:100-102.
85. Rothschild MA, Rothschild AH, Pfeifer MA. The inotropic action of tolbutamide and glyburide. Clin Pharmacol Ther 1989;45:642-649.
86. Hildner FJ, Yeh BK, Javier RP, Fester A, Samet P. Inotropic action of tolbutamide on human myocardium. Cathet Cardiovasc Diagn 1975;1:47-57.
87. Sykes CA, Wright AD, Malins JM, Pentecost BL. Changes in systolic time intervals during treatment of diabetes mellitus. Br Heart J 1977;39:255-259.
88. Dubach UC, Burckhardt D, Raeder EA, et al. Effect of intravenous glibornuride and tolbutamide on myocardial contractility. Cardiology 1979;64:208-214.